恒瑞医药四款药物临床试验获批

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of multiple drugs, indicating progress in its oncology pipeline [1] Group 1: Clinical Trials - The company and its subsidiaries, Chengdu Shengdi Pharmaceutical Co., Ltd. and Shanghai Heng Rui Medicine Co., Ltd., have been granted clinical trial approval for SHR-4394, HRS-5041 tablets, Zemeituosita tablets (SHR-2554), and Rivirolem tablets [1] - The specific focus of the clinical trials will be on the safety, tolerability, and efficacy of SHR-4394 or HRS-5041 in combination with anti-tumor treatment in participants with prostate cancer [1]